{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:05:10Z","timestamp":1792821910451,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001637","name":"Trinity College Dublin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omtm.2025.101450","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:45:35Z","timestamp":1741923935000},"page":"101450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Avril","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Sophia","family":"Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Santos-Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-240X","authenticated-orcid":false,"given":"Matthew","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101450_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet. Glob. Health"},{"key":"10.1016\/j.omtm.2025.101450_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis."},{"key":"10.1016\/j.omtm.2025.101450_bib3","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib6","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib7","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","article-title":"Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation","volume":"159","author":"Cho","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101450_bib13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101450_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/IAE.0000000000001765","article-title":"MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION","volume":"38","author":"Kuroda","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.omtm.2025.101450_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.omtm.2025.101450_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/bjophthalmol-2018-312430","article-title":"Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen","volume":"103","author":"Mantel","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101450_bib19","first-page":"S2","article-title":"Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.omtm.2025.101450_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100306","article-title":"Geographic Atrophy in Age-Related Macular Degeneration: A Tale of Two Stages","volume":"3","author":"Keenan","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"10.1016\/j.omtm.2025.101450_bib21","article-title":"Nutritional and Lifestyle Interventions for Age-Related Macular Degeneration: A Review","volume":"2017","author":"Carneiro","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.omtm.2025.101450_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1096\/fasebj.14.7.835","article-title":"Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease","volume":"14","author":"Mullins","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.omtm.2025.101450_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2025.101450_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101450_bib25","first-page":"3861","article-title":"Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels","volume":"24","author":"Kavanagh","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101450_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJMoa072618","article-title":"Complement C3 variant and the risk of age-related macular degeneration","volume":"357","author":"Yates","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101450_bib27","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1167\/iovs.12-9587","article-title":"Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration","volume":"53","author":"Loyet","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101450_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9945725","article-title":"Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option","volume":"2021","author":"Qin","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omtm.2025.101450_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ajo.2024.02.021","article-title":"Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go","volume":"263","author":"Csaky","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101450_bib30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101450_bib31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2\/3 Trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2025.101450_bib32","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101450_bib33","unstructured":"NCT03525600 (2023). Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration."},{"key":"10.1016\/j.omtm.2025.101450_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019078","article-title":"A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration","volume":"6","author":"Cashman","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101450_bib35","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1167\/iovs.08-2025","article-title":"Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE","volume":"49","author":"Ramo","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101450_bib36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-023-36441-z","article-title":"Structural basis for membrane attack complex inhibition by CD59","volume":"14","author":"Couves","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101450_bib37","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1016\/S0021-9258(18)42266-1","article-title":"The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the \u201cb\u201ddomain of C9","volume":"267","author":"Ninomiya","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101450_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.exer.2019.05.006","article-title":"The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials","volume":"184","author":"Kumar-Singh","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2025.101450_bib39","unstructured":"NCT03144999 (2021). Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59."},{"key":"10.1016\/j.omtm.2025.101450_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/OPTH.S367089","article-title":"Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration","volume":"17","author":"Khan","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101450_bib41","first-page":"732","article-title":"Pooled safety analysis of a single intravitreal injection of JNJ-1887 (gene therapy, AAVCAGsCD59) in patients with age-related macular degeneration (AMD)","volume":"64","author":"Lad","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101450_bib42","unstructured":"NCT03585556 (2022). AAVCAGsCD59 for the Treatment of Wet AMD."},{"key":"10.1016\/j.omtm.2025.101450_bib43","series-title":"Aflibercept","author":"Adams","year":"2023"},{"key":"10.1016\/j.omtm.2025.101450_bib44","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.1038\/s41598-021-87340-6","article-title":"Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease","volume":"11","author":"Tanaka","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2025.101450_bib45","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101450_bib46","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101450_bib47","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000520171","article-title":"Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment","volume":"245","author":"Foss","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.omtm.2025.101450_bib48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41434-024-00461-1","article-title":"Stable inhibition of choroidal neovascularization by adeno-associated virus 2\/8-vectored bispecific molecules","volume":"31","author":"Bai","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101450_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/ar2019","article-title":"Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis","volume":"8","author":"Kinderlerer","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtm.2025.101450_bib50","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molmed.2016.06.009","article-title":"A revised hemodynamic theory of age-related macular degeneration","volume":"22","author":"Gelfand","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtm.2025.101450_bib51","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bbrc.2017.09.019","article-title":"Shear stress-mediated changes in the expression of complement regulatory protein CD59 on human endothelial progenitor cells by ECM-integrin\u03b1V\u03b23-F-actin pathway in vitro","volume":"494","author":"Cui","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtm.2025.101450_bib52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","article-title":"Anti-VEGF treatment patterns for neovascular age-related macular degeneration among Medicare beneficiaries","volume":"158","author":"Lad","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101450_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/tjo.28003","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turk. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101450_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:48:36Z","timestamp":1759862916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2329050125000452"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101450","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101450"}}